Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Shukra Pharmaceuticals met on December 30, 2025 and approved three main items. First, Mr. Dinesh Chauhan (DIN: 11456530) was appointed as an Additional Non-Executive Independent Director for three years, subject to shareholder approval. He has over 7 years of experience in business management and operations. Second, the board accepted the resignation of Ms. Bhoomi Patel (DIN: 08316893) as Independent Director effective the same day, citing personal reasons. Third, the Audit Committee, Nomination & Remuneration Committee, and Stakeholders' Relationship Committee were reconstituted with Mr. Dinesh Chauhan now chairing all three committees, alongside Mrs. Sonal Deepalbhai Gandhi and Mr. Sarjeevansingh Rathore as members. The company confirmed the incoming director is not related to any existing board member and is not debarred by SEBI.
This is a routine governance change with one independent director stepping down for personal reasons and being immediately replaced by another independent director, keeping board composition balanced. No material financial or strategic impact is expected for shareholders.